Q2 2025 Management View CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the first ...

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Qure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

Qure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.

What happenedShares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter ...

uniQure N.V. (QURE) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

The stock price of uniQure, a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0.79 per share ...

The stock price of uniQure stock, a gene therapy company, has seen a a large 13% drop over the last five trading days. The company recently announced that the U.S. FDA has asked for eighteen ...

The uniQure gene therapy is being tested in an open-label Phase 3 study that dosed 54 patients, each of them given a single infusion. The main goal was to measure FIX levels at 26 weeks.

What happened Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is ...